News

NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Intravenous Therapy and Intravenous Access Market Size, Share and Industry Trends Analysis Report, Outlook and Forecast by End User, Application, Type, Region , 2022-2028″ – https://www.reportlinker.com/p06283441/?utm_source=GNW The fastest way to infuse fluids into different parts of the body is through IV therapy.Heart attack, stroke, and poisoning are all treated with this drug.In this case, the patient should be treated with the drug as soon as possible, thus giving the drug intravenously.Chemotherapy treatments, antibiotics, antifungals, pain relievers, immune globulin treatments, and blood pressure drugs are given intravenously.Intravenous therapy (IV) is a method of delivering medicines and fluids into the body through a vein.Medications containing vitamins and minerals are given by intravenous drip or intravenous injection, allowing the treatment to flow quickly through the bloodstream.According to Scope, IV administration is when the patient uses a tube called a cannula to put substances directly into a vein.This could be a side effect of a medication or a nutritional deficiency.IV therapy is the typical way to provide fluids, drugs, chemotherapy, and blood transfusions to dehydrated patients.During IV administration, various IV equipment such as IV catheters, infusion pumps, immobilization devices, and administration kits are used.IV therapy administration is fast, easy to follow, and has no gastrointestinal side effects.It promotes a faster immune system response and relieves chronic diseases than oral therapy.It has an infusion pump that controls the amount of chemicals to be supplied to the body and can be easily monitored.The global intravenous therapy and intravenous access devices market is expected to increase over the forecast period.The prevalence of diabetes, rising incidence of traffic accidents, and increase in surgical procedures are expected to propel the industry forward.The industry is also driven by growing demand for sophisticated methods, such as needle-free drug delivery.COVID-19 Impact COVID-19 has a positive overall impact on the IV therapy market.In patients with severe COVID-19-related acute respiratory distress syndrome, IV therapy (ARDS) is administered.For example, the use of intravenous immune globulin for the treatment of COVID-19 ARDS as an attractive adjuvant for the treatment of severe COVID-19-related ARDS was published in The Lancet Respiratory Medicine on November 11, 2021 because it Ability to modulate multiple immune compartments simultaneously.Therefore, with the increase in the number of patients with COVID-19-related ARDS, the demand for IV therapy and intravenous access products increases.Market Growth Factors Increasing Operations and Growing Geriatric Population The prevalence of various chronic diseases requiring vascular access therapy has increased over the past decade.Chronic diseases such as cancer, kidney failure and heart disease, as well as various lifestyles such as high blood pressure, diabetes, obesity and depression, require intensive care during hospital stays.Over the next few years, the increasing burden of chronic diseases such as cardiovascular disease, cancer, stroke, and diabetes, coupled with an aging population, will increase the need for intravenous therapy.Technological Advances Intravenous catheters (peripheral and central), accessories with safety devices, and tip infusion pumps are among the technical resources that contribute to safer, higher-quality intravenous therapy (IVT) practice.As health technology is a complex discipline, with reflection and discussion on a daily basis by health professionals involved in patient care in the intensive care unit, the field of care has undergone significant changes due to the incorporation of new technologies, and cutting-edge infusion pumps are One of the technical resources to help achieve safer and higher quality intravenous therapy (IVT) practice.Market Constraints Pump manufacturing requires stringent regulations and concerns about complications. The licensing process for new projects is being driven around pump production and consolidation.Additionally, rising product recalls due to manufacturing defects will slow the adoption of these therapies.For example, Fresenius Kabi recalled the Vigilant Agilia Drug Depot and Volumat MC Agilia Infusion Pump in August 2019 due to infusion alert issues, low-priority Keep Vein Open (KVO) and other software bugs.A major impediment to the growth of the industry is the complications associated with the use of IV methods and IV infusion products.End User Outlook Based on end user, the market is segmented into hospitals, ambulatory surgery centers, and clinics.The hospital segment will capture the largest revenue share in the intravenous (IV) treatment and venous access market in 2021.This is due to an increase in the number of surgeries performed compared to ambulatory surgery centers and clinics.In addition, the growth of the segment was attributed to the increased use of intravenous therapy in hospitals, which includes intravenous antibiotic therapy, drugs for comatose patients, drugs that cannot be taken orally, interventional radiology, anticancer drugs, hemodialysis, repeat blood sample mapping, and blood transfusions .The market for IV therapy and venous access devices is growing due to technological advancements and hospital investments.Application Outlook On the basis of application, the market is segmented into drug administration, blood-based products, nutritional and buffer solutions, and expansion vessels.In 2021, the Volume Expander segment will gain significant revenue share in the intravenous (IV) therapy and venous access market.Intravenous fluids may be useful for a small number of fluid-sensitive athletes; however, this should be reserved for high-level athletes with a history of strong symptoms under good monitoring.Some athletes may benefit from using an expander.Intravenous fluids and plasma binders are prohibited in WADA-controlled competitions.For the vast majority of athletes, routine IV therapy is not the best option.Type Outlook Based on type, the market is segmented into intravenous catheters, infusion pumps, hypodermic needles, implantable ports, and others.In 2021, the intravenous catheter segment will capture the largest revenue share in the intravenous (IV) therapy and venous access market.This is due to the increased use of IV catheters during surgical procedures for IV therapy and during the transfer of blood, medications, and other nutrients to various parts of the body.Intravenous catheters are tiny tubes placed in a body cavity or lumen.An intravenous catheter is an intravenous catheter used to deliver drugs, fluids, or other therapies directly into the bloodstream.They are most often introduced into a vein in the arm, although they can also be inserted into the neck, chest, or groin.Intravenous catheters come in a variety of sizes and forms, depending on their intended use.Regional Outlook Based on region, the market is segmented into North America, Europe, Asia Pacific & Latin America, Middle East & Africa.In 2021, North America is the leading region in the intravenous (IV) therapy and venous access market by capturing the highest market revenue share.The growth of the regional market can be attributed to the increase in the number of patients, rising incidence of traffic accidents, high growth in trauma cases, and increasing federal investments in developing better medical facilities and R&D activities.The market research report covers the analysis of the key stakeholders of the market.Major companies profiled in the report include B. Braun Melsungen AG, Medtronic PLC, Terumo Corporation, Fresenius SE & Co. KGaA, Cardinal Health, Inc., Pfizer, Inc., Teleflex, Inc., Baxter International, Inc., Smiths Group PLC and AngioDynamics, Inc. Deploy Strategies in the Intravenous (IV) Therapy and Intravenous Access Market March 2022: Fresenius Kabi signed an agreement to acquire Fresenius Kabi, a global healthcare company.The acquisition, designed to integrate Ivenix’ enhanced infusion systems into Fresenius Kabi’s portfolio of intravenous infusion and infusion therapy products, will bring a broad mix of products to U.S. hospitals.December 2021: Baxter forms partnership with US medical technology provider Hillrom.Through this collaboration, the two companies aim to bring together two major medical technology businesses to achieve a shared vision of transforming global healthcare and improving patient care.May 2021: Smiths Medical forms partnership with medical technology company Ivenix.Through this partnership, the two companies aim to offer a broad range of infusion management solutions.Additionally, Smiths Medical will provide strategic investments in long-term partnerships designed to revolutionize mixing management and enhance patient health, while meeting the needs of healthcare providers.April 2021: B. Braun Medical launched a new program, Peripheral Advantage, to improve patients’ experience with peripheral intravenous therapy.The program integrates clinical guidance, data-driven intuition, and improved tools to empower nurses to achieve first-hand success and help avoid the complexities associated with peripheral IV therapy.July 2019: Baxter receives U.S. Food and Drug Administration (FDA) approval for Myxredlin.The approval allows for immediate insulin for intravenous infusion in hospitals and other intensive care settings and has an extensive shelf life of 30 days or 24 months at room temperature if refrigerated in the original packaging to ensure protection from light.Reports: By End User • Hospitals • Ambulatory Surgery Centers • Clinics by Application • Medication Administration • Blood Products • Nutrients and Buffer Solutions • Diffusion Vessels by Type • Intravenous Catheters • Infusion Pumps • Hypodermic Needles • Implantable Ports • Other by Geography • North America o USo Canadao Mexico Rest of North America • Europe Germany o UKo France Russia Spain Italy o Rest of Europe • Asia Pacific China o Japan India Korea Singapore Malaysia o Rest of Asia Pacific • LAMEAo Brazil Argentina UAE Saudi Arabia South Africa Nigeria LAMEA Rest Company Profile• B. Braun Melsungen AG • Medtronic PLC• Terumo Corporation• Fresenius SE & Co. KGaA• Cardinal Health, Inc.• Pfizer, Inc.• Teleflex, Inc.• Baxter International, Inc.• Smiths Group PLC• AngioDynamics, Inc. Unique Offerings • Exhaustive Coverage • Most Extensive Market Tables & Data • Subscription-Based Model Available • Best Price Guaranteed • Guaranteed Post-Sale Research Backed by 10% Customization Read the full report for free: https://www .reportlinker.com/p06283441/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution.Reportlinker finds and organizes the latest industry data so you can get all the market research you need right away in one place.______________________________